Objective: The aim of this pilot study was to assess if a FiASP-and-pramlintide artificial pancreas (AP) could alleviate the need for CHO counting by using a simple meal announcement system (pressing a button, no CHO counting) without degrading glycemic control.

Methods: We conducted a 24-hour inpatient, randomized, crossover, non-inferiority, pilot study to compare (i) FiASP AP with full CHO counting (FCC) and CHO-matched boluses with (ii) FiASP-and-pramlintide AP with simple meal announcement (SMA). Pramlintide and FiASP were delivered in a basal-bolus manner using a fixed ratio (1U: 10µg).

Results: Seven participants (age 26.2±16, HbA1c 8.4±0.8%) were included in the analysis. The time in range (3.9-10 mmol/L) was 85.7% (IQR: [72-93]) in the FCC arm and 87.3% [75-95] in the SMA arm (p=0.21). Time spent >10mmol/L did not differ between interventions (FCC: 11.4% [0.9-22], SMA: 10.1% [3.1-25], p=0.38). Time <3.9mmol/L was lower in the SMA arm (2.1% vs. 4.1%, p=0.02). One participant experienced persistent GI symptoms in the SMA arm.

Conclusions: The FiASP-and-pramlintide SMA system has the potential of reducing the burden of CHO counting without degrading glucose control. Outpatient studies are warranted.

graphic
View largeDownload slide
Disclosure

M. Tsoukas: Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk Inc. Speaker’s Bureau; Self; Boehringer Ingelheim (Canada) Ltd., Janssen Scientific Affairs, LLC. E. Palisaitis: None. J. Rutkowski: None. J.E. von Oettingen: None. L. Legault: Advisory Panel; Self; Dexcom, Inc., Lilly Diabetes. Research Support; Self; AstraZeneca K.K., Merck & Co., Inc., Sanofi-Aventis. Other Relationship; Self; Lilly Diabetes. J. Yale: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Board Member; Self; Diagnos. Research Support; Self; Bayer Inc., Novo Nordisk A/S, Sanofi. Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Novo Nordisk A/S, Sanofi. A. Haidar: Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc., Eli Lilly and Company.

Funding

JDRF (2-SRA-2018-654-M-B)

© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.